Spravato (esketamine) treatments represent a novel approach in psychiatric care, specifically targeting treatment-resistant depression (TRD) and major depressive disorder (MDD) with acute suicidal ideation or behavior. Approved by the FDA in 2019, Spravato is administered intranasally under medical supervision in a healthcare setting.
BENEFITS OF SPRAVATO TREATMENTS
The mechanism of action of Spravato involves modulation of the glutamate system in the brain, which is different from traditional antidepressants that primarily affect serotonin and other neurotransmitters. This unique approach makes Spravato particularly beneficial for individuals who have not responded adequately to other treatments. Overall, Spravato treatments offer a promising option for those with severe and treatment-resistant depression, aiming to provide rapid relief of symptoms and improve overall quality of life under careful medical supervision.
Questions About Spravato?
Click here to download the Spravato Patient Brochure
WHAT TO EXPECT
During Spravato treatment sessions, a patient self-administers the nasal spray under the supervision of a trained Healthcare Provider. The session typically lasts about two hours, which includes preparation, administration, and monitoring for any potential side effects. After administration, patients are observed for a period of time to ensure safety and monitor their response to the medication. The treatment schedule typically involves twice-weekly sessions for the first month, followed by weekly or biweekly sessions depending on individual response and clinical judgment.